Family history and risk of colorectal cancer: implications for screening programmes

Citation
Am. Benhamiche-bouvier et al., Family history and risk of colorectal cancer: implications for screening programmes, J MED SCREE, 7(3), 2000, pp. 136-140
Citations number
28
Categorie Soggetti
Envirnomentale Medicine & Public Health
Journal title
JOURNAL OF MEDICAL SCREENING
ISSN journal
09691413 → ACNP
Volume
7
Issue
3
Year of publication
2000
Pages
136 - 140
Database
ISI
SICI code
0969-1413(2000)7:3<136:FHAROC>2.0.ZU;2-I
Abstract
Objective-To estimate the lifetime risk of colorectal cancer in the general population and in first degree relatives of patients with sporadic colorec tal cancer or adenoma. Main outcomes measures The cumulative risk of colorectal cancer (0-74) in t he general population combined with the relative risk of colorectal cancer and the prevalence of different groups of subjects with family history of c olorectal tumour allows the calculation of cumulative risks in these groups . Results-The lifetime risk of colorectal cancer was 1 in 23 in men and 1 in 40 in women. In males, 0.5% in the 55-59 age group and 4.5% in the 70-74 ag e group will develop a colorectal cancer. The corresponding values in femal es were 0.4% and 2.5%. The cumulative risk at age 74 varied between 7.7% to ne family member affected) and 25.6% (two affected) in males, and 4.3% and 14.3% respectively in females. The risk in the 40-44 year age group for ind ividuals with one first degree relative affected before 45 years of age was 0.5%, similar to that of those aged 45-49 with one first degree relative a ffected with a colorectal cancer or a large adenoma (> 1 cm). Conclusions-These results suggest that screening in the general population should start at 50 or 55. The Lifetime risk is high enough lover 10%) among individuals with one affected first degree relative before age 45, or with at least two affected first degree relatives, to warrant colonoscopic scre ening. The data provide a basis for recommendations that relatives of these patients should enter screening programmes at age 40 to 44.